Biogen Inc.BIIBNASDAQ
LOADING
|||

Company Overview

: BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Key Statistics

Market Cap
$26.16B
Price
$178.30
Volume
1.56M
Employees
13.41K
IPO Date
N/A
Currency
USD

Industry Classification

Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology (except Nanobiotechnology)

Company Information

Chief Executive Officer
George Scangos
Headquarters
225 Binney St, Cambridge, Massachusetts 02142-1031
Country
US
Phone
17814642000